Gene Therapy FDA Approval for Rare Disease: Updated List and Analysis

Gene Therapy FDA Approval for Rare Disease: Updated List and Analysis

Only about 5% of rare diseases have an FDA-approved drug, but gene therapies are gaining ground. This analysis covers the latest FDA approved gene therapy list, including the recent approval of Kresladi for LAD-I, and what it means for pharma teams and investors.

IntelligenceRegulatory Impact▾

FDA decisions frame this story. Regulatory relevance is high for rare disease. Track designations, submission types, and label or guidance shifts that could move timelines.

Key takeaways

• Only about 5% of rare diseases have an FDA-approved drug, underscoring a massive unmet need that gene therapies are beginning to fill.
• The FDA approved Kresladi (marnetegragene autotemcel) as the first gene therapy for severe LAD-I, adding a critical new entry to the FDA approved gene therapy list.
• For pharma BD and investors, this approval signals continued regulatory support for gene therapies in rare diseases and reinforces the potential for market expansion in a space where most conditions still lack any approved treatment.

IntelligenceMarket Signals▾

Commercial pull is high and investment relevance high for rare disease. Expect implications for pricing, access, and launch sequencing.

The development: Kresladi joins the FDA approved gene therapy list

On September 18, 2023, the FDA approved Kresladi (marnetegragene autotemcel) as the first gene therapy for the treatment of severe Leukocyte Adhesion Deficiency Type I (LAD-I), a rare pediatric immune disorder that typically proves fatal without a bone marrow transplant. The approval, announced in an FDA press release, adds a new entry to the FDA approved gene therapy list, which now includes therapies for a growing set of rare diseases.

The decision underscores the FDA's willingness to advance gene therapies for conditions with limited treatment options. LAD-I affects fewer than 1,000 patients in the U.S., making it a textbook rare disease target for a one-time gene therapy. Kresladi is an autologous hematopoietic stem cell-based gene therapy, meaning a patient's own cells are modified ex vivo and reinfused — a manufacturing model that BD teams will recognize as capital-intensive but potentially durable in pricing and patient outcomes.

IntelligenceStrategic Takeaways▾

Only about 5% of rare diseases have an FDA-approved drug, underscoring a massive unmet need that gene therapies are beginning to fill. The FDA approved Kresladi (marnetegragene autotemcel) as the first gene therapy for severe LAD-I, adding a critical new entry to the FDA approved gene therapy list. For pharma BD and investors, this approval signals continued regulatory support for gene therapies in rare diseases and

Implications for pharma teams

For BD teams and investors, the Kresladi approval reinforces the viability of gene therapy as a treatment modality for rare diseases. The FDA approved gene therapy list now includes multiple products spanning hemophilia, spinal muscular atrophy, certain inherited retinal diseases, and now LAD-I. Each approval builds a stronger case for the regulatory pathway, potentially lowering the risk profile for pipeline programs targeting similarly small patient populations.

Companies with gene therapy pipelines targeting rare diseases should monitor both regulatory trends and competitive dynamics closely. The approval also highlights the importance of manufacturing and commercialization strategies for gene therapies, which often require specialized infrastructure and cold-chain logistics. For investors tracking the gene therapy fda approval rare disease list, the expansion signals that the FDA is not slowing down its review of these products, even as it asks for longer follow-up data on durability and safety.

One statistic should focus any BD strategy: a comprehensive study published in PMC concluded that around 5% of rare diseases have an FDA-approved drug, and up to 15% have at least one drug that has shown promise. That leaves an enormous gap for gene therapies to address, and the FDA's track record suggests it will continue to facilitate these approvals when the data hold up.

IntelligenceEvidence Quality▾

Grounded in 1 regulatory source and 1 peer-reviewed source.

Tracking the FDA approved gene therapy list

As of late 2023, the FDA approved gene therapy list includes products like Luxturna (for inherited retinal dystrophy), Zolgensma (for spinal muscular atrophy), and now Kresladi. The first gene therapy approved by FDA in the U.S. was Kymriah in 2017, though that is classified as a CAR-T cell therapy. For those tracking the approved cellular and gene therapy products, the distinction matters: gene therapies that modify a patient's own cells in vivo or ex vivo sit alongside cell therapies in the FDA's regulatory framework, but they carry different manufacturing and durability profiles.

Investors often ask: how many FDA approved gene therapies are there? The answer depends on whether you count only in vivo gene therapies or include ex vivo modified cell therapies. The FDA's own list of approved cellular and gene therapy products provides the most authoritative count, but the broader point for BD teams is that the pipeline is accelerating, and each new approval on the gene therapy fda approval rare disease list opens up commercial playbooks that can be adapted for the next candidate.

Frequently Asked Questions

Related coverage

• Exclusive: FDA issues industry-friendly gene therapy guidance: What BD teams need to know
• FDA Issues June 2026 Guidance: Gene Therapy, Payor Comms, and CMC Flexibilities
• AI Citation Gap in CDMO Capacity: Pharmaceutical Manufacturing Examples and Insights